drugset / Trial / NCT00102336

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

NCT00102336

Phase 3 Completed 62 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response. This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531.

Timeline

Start
2005-04-07
Primary completion
2006-12-01
Completion
2007-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim Peptide 1 ug/kg Subcutaneous
Subject Romiplostim Peptide 15 ug/kg Subcutaneous